- Home
- ALUR vs ALXO Comparison
ALUR vs ALXO Comparison
Compare ALUR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALUR
- ALXO
- Stock Information
- Founded
- ALUR 2009
- ALXO 2015
- Country
- ALUR United States
- ALXO United States
- Employees
- ALUR N/A
- ALXO N/A
- Industry
- ALUR
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- ALUR
- ALXO Health Care
- Exchange
- ALUR Nasdaq
- ALXO Nasdaq
- Market Cap
- ALUR 21.1M
- ALXO 24.0M
- IPO Year
- ALUR N/A
- ALXO 2020
- Fundamental
- Price
- ALUR $2.40
- ALXO $0.64
- Analyst Decision
- ALUR Strong Buy
- ALXO Strong Buy
- Analyst Count
- ALUR 3
- ALXO 6
- Target Price
- ALUR $22.83
- ALXO $3.30
- AVG Volume (30 Days)
- ALUR 68.8K
- ALXO 563.3K
- Earning Date
- ALUR 08-13-2025
- ALXO 08-12-2025
- Dividend Yield
- ALUR N/A
- ALXO N/A
- EPS Growth
- ALUR N/A
- ALXO N/A
- EPS
- ALUR N/A
- ALXO N/A
- Revenue
- ALUR $28,304,000.00
- ALXO N/A
- Revenue This Year
- ALUR N/A
- ALXO N/A
- Revenue Next Year
- ALUR $49.37
- ALXO N/A
- P/E Ratio
- ALUR N/A
- ALXO N/A
- Revenue Growth
- ALUR N/A
- ALXO N/A
- 52 Week Low
- ALUR $2.15
- ALXO $0.40
- 52 Week High
- ALUR $22.25
- ALXO $2.79
- Technical
- Relative Strength Index (RSI)
- ALUR 34.20
- ALXO 57.73
- Support Level
- ALUR $2.30
- ALXO $0.60
- Resistance Level
- ALUR $2.69
- ALXO $0.69
- Average True Range (ATR)
- ALUR 0.18
- ALXO 0.06
- MACD
- ALUR -0.06
- ALXO 0.00
- Stochastic Oscillator
- ALUR 14.29
- ALXO 63.95
About ALUR Allurion Technologies Inc.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.